Diet Pills Central: news - Weight Loss Drugs

Weight Loss Drugs - Experts Criticize Diet Pills Searching for FDA Approval

neomedia.ro — 2006-02-16T15:32:28

Near the end of the last May, University of Kansas student Nicole wanted to cut 30 pounds from her 5-foot-9, 173-pound frame. Her lifestyle at that time was not suitable to losing the weight. Diet pills presented a reasonable alternative.

Weight Loss Drug - 2 New Obesity Drugs Up for FDA Approval

neomedia.ro — 2006-02-16T15:02:54

The U.S. Food and Drug Administration is expected to rule soon on two new weight-loss pills.

Diet Drug - Fat Rats Give Clue to Obesity

neomedia.ro — 2006-02-16T14:57:53

An experiment reducing the level of a chemical in rats’ brains offers a promising strategy for new obesity drugs.

Diet drug - Newly found hormone may decrease appetite

neomedia.ro — 2005-11-11T15:41:45

Stanford University scientists have discovered a potential new weapon in the battle of the bulge: a hormone that reduces the urge to eat.

Weight Loss Drug - Alizyme Successfully Completes Clinical Trial for Cetilistat in the USA

neomedia.ro — 2005-11-11T15:13:18

Alizyme plc (LSE:AZM) has successfully completed its pharmacokinetic/pharmacodynamic clinical trial of cetilistat in obese volunteers, under its Investigational New Drug (IND) application in the USA.

Weight Loss Drug - USU working on innovative diet drug

neomedia.ro — 2005-11-11T14:53:45

Utah State University researchers are hoping to pave the way for an efficient appetite-suppressant drug. The idea is for a diet drug to be ingested and, instead of the medication spreading throughout the entire body, the drug would be sent via small particles, targeting specific cells in the digestive system. This would mean better control of a person's desire for food intake, resulting in weight loss.

Weight Loss Drug - Newborn Brain Cells Could Regulate Weight

neomedia.ro — 2005-11-11T14:42:14

For the first time, scientists have linked the growth of new brain cells--induced by a compound known as ciliary neurotrophic growth factor (CNTF)--with weight loss in mice. The findings could offer an explanation for why use of the compound in previous studies kept mice at a healthy weight weeks and months after injections of the drug were stopped.

Diet Drug - Arena's APD356 Phase 2a Clinical Trial Data Presented at the 2005 NAASO Annual Meeting

neomedia.ro — 2005-11-11T14:08:30

Arena Pharmaceuticals, Inc. announced today that data from its positive Phase 2a clinical trial studying APD356 in 352 obese patients was the subject of a presentation by Steven Smith, M.D., Principal Investigator and Associate Professor of the Pennington Biomedical Research Center, at the 2005 annual meeting of the North American Association for the Study of Obesity (NAASO). Over the 28-day treatment period in the trial, there was a highly statistically significant (p=0.0002) mean placebo adjusted weight loss of approximately 1 kilogram in patients taking the 15 mg dose of APD356. APD356 was generally well tolerated at all doses investigated in the trial. APD356 is a selective agonist of 5-HT2C serotonin receptors, which are located in the hypothalamus, an area of the brain known to play an important role in regulating food intake and metabolism.

Diet pill - Little babies could teach us a lot about how and when to eat

neomedia.ro — 2005-11-11T13:18:25

British researchers think they've found a new solution to the perpetual problem of insatiability, one they believe also could help stem the world's swelling obesity epidemic. All we need to do is trick the brain into thinking we've had dinner before actually eating.

New Weight Loss Pill on Tests: A Metabolism Enhancer Changing Muscle Structure

neomedia.ro — 2004-12-20T18:01:58

GlaxoSmithKline is currently testing a weight loss pill that brings new hope for the persons with weight problems: the pill activates a protein called PPAR-delta. The pill was created as the result of studies on the effects of enhanced PPAR-delta on mice muscle and metabolism. Initially, the effect of PPAR-delta activation was obtained by modifying genetically the mice. The new drug, called GW501516, activates PPAR-delta directly.